drugset / Trial / NCT00265135
A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to better understand the safety, tolerability and distribution of CNTO 328 in the bloodstream.
Timeline
- Start
- 2003-08
- Primary completion
- 2006-02
- Completion
- 2006-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siltuximab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Siltuximab | Monoclonal antibody | 12 mg/kg | Intravenous |